MiniMed Group (NASDAQ:MMED) Releases Earnings Results, Misses Expectations By $0.46 EPS

MiniMed Group (NASDAQ:MMED) released its earnings results on Wednesday. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46), Briefing.com reports. The firm had revenue of $837.00 million during the quarter. The company’s quarterly revenue was up 15.6% on a year-over-year basis.

Here are the key takeaways from MiniMed Group’s conference call:

• MiniMed reported record fiscal 2026 revenue above $3 billion, with 8% organic growth for the year and 8.7% organic growth in Q4, driven largely by international strength and recurring revenue streams.
• U.S. Q4 growth of 1.5% fell below expectations, but management said the shortfall was mainly a timing issue tied to patients waiting for the upcoming MiniMed Flex launch rather than a demand problem.
• The company highlighted multiple product launches supporting FY2027 growth, including MiniMed Go now launched in the U.S., MiniMed Flex pre-orders underway with shipments coming later this month, and the Instinct sensor rolling out in Europe soon.
• Recurring revenue momentum continued, with CGM attachment rising to 68% in Q4 and 66% for the full year, while global pump users increased 4% year over year to 659,000.
• MiniMed guided to about 10% organic revenue growth in fiscal 2027 and an adjusted EBITDA margin of roughly 16%, saying the outlook is supported by new product launches but that growth will build progressively through the year.

MiniMed Group Stock Up 15.9%

Shares of MMED stock opened at $14.26 on Thursday. MiniMed Group has a twelve month low of $10.65 and a twelve month high of $20.48. The stock’s fifty day simple moving average is $12.96.

Analyst Ratings Changes

Several analysts recently weighed in on MMED shares. Evercore started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set an “outperform” rating and a $20.00 price objective for the company. The Goldman Sachs Group started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $24.00 price objective for the company. Piper Sandler started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “neutral” rating and a $16.00 price objective for the company. Citigroup started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $23.00 price objective for the company. Finally, BTIG Research started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MiniMed Group currently has an average rating of “Moderate Buy” and an average target price of $21.67.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.